Worldwide licensing of pandemic technologies is already current practice. The Pandemic Accord should protect...
The negotiations for a WHO pandemic accord are still in full swing this week. Talks are taking place behind closed doors, but it is...
Will the European Court of Justice put a stop to the evergreening of Truvada...
Truvada, the fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is a critical medicine in both HIV treatment and prevention. It is...
Covid-19 intellectual property pool gaining support
While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should...
How not to solve a crisis: The European Commission’s Plan for Transferable Data Exclusivity...
Drug-resistant infections, sometimes called “superbugs,” killed an estimated 1.27 million people in 2019, a number set to rise to 50 million by 2050. It is...
Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda
On Thursday 24 January, the World Health Organization’s 144th Executive Board meeting will kick off in Geneva. One of the agenda items is access...
Decision on intellectual property waiver over Covid technology on hold till 2021; what are...
Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer.
The...
WHO is an essential forum for debates on intellectual property and public health
Recently, Health Policy Watch reported that some European countries at the World Health Organization (WHO) Pandemic Agreement negotiations maintain that intellectual property negotiations belong...
The Italian Exception – A personalised approach to accessing high-priced patented medicines
At the end of March 2017, the Italian Minister of Health Beatrice Lorenzin has authorised the importation of generic medicines. She did this with...
Uganda tells ARIPO: No more patents for pharmaceuticals
Uganda has notified the African Regional Intellectual Property Organisation (ARIPO) that pharmaceutical inventions are not eligible for patentability in the country, Managing IP reported.
With...
Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...
On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...